Biologics contract manufacturing sales will expand through 2036, with monoclonal antibodies holding 25.3% of the product type segment in 2026, driven by expanding biologic drug pipelines and increasing outsourcing by biopharma companies. The market was valued at USD 35.20 billion in 2025 and is expected to be worth USD 103.48 billion by 2036.